Spatiotemporal PET Imaging of Dynamic Metabolic Changes After Therapeutic Approaches of Induced Pluripotent Stem Cells, Neuronal Stem Cells, and a Chinese Patent Medicine in Stroke

Zhang, Hong; Song, Fahuan; Xu, Caiyun; Líu, Hao; Wang, Zefeng; Li, Jinhui; Wu, Shuang; YehuaShen,; Chen, Yao; Zhu, Yi; Du, Ruili; Tian, Mei

doi:10.2967/jnumed.115.163170

Cited by 21 publications

(17 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positron emission tomography (PET), serving as the representative molecular imaging modality, enables noninvasive visualization of molecular changes during biological processes in vivo by utilizing radiolabeled molecules . PET imaging with [ 18 F]fluoro-2-deoxyglucose ( 18 F-FDG), a glucose analog, has been used to detect subtle glucose metabolic alterations in vivo in a wide range of neurological diseases. , In this study, significantly higher 18 F-FDG uptake was observed in the ipsilateral ischemic brain area in the HPBZs-pretreated group than in the saline-pretreated MCAO group (Figure a,c, P < 0.05), suggesting that HPBZs pretreatment ameliorated cerebral glucose metabolic damage. Twenty-four hours after 18 F-FDG PET imaging, rat brains were extracted, sliced, and stained with 2,3,5-triphenyltetrazolium chloride (TTC).…”

mentioning

confidence: 61%

Hollow Prussian Blue Nanozymes Drive Neuroprotection against Ischemic Stroke via Attenuating Oxidative Stress, Counteracting Inflammation, and Suppressing Cell Apoptosis

et al. 2019

Self Cite

View full text Add to dashboard Cite

Ischemic stroke is a devastating disease and one of the leading causes of mortality worldwide. Overproduction of reactive oxygen and nitrogen species (RONS) following ischemic insult is known as a key factor in exacerbating brain damage. Thus, RONS scavengers that can block excessive production of RONS have great therapeutic potential. Herein, we propose an efficient treatment strategy in which an artificial nanozyme with multienzyme activity drives neuroprotection against ischemic stroke primarily by scavenging RONS. Specifically, through a facile, Bi 3+ -assisted, template-free synthetic strategy, we developed hollow Prussian blue nanozymes (HPBZs) with multienzyme activity to scavenge RONS in a rat model of ischemic stroke. The comprehensive characteristics of HPBZs against RONS were explored. Apart from attenuating oxidative stress, HPBZs also suppressed apoptosis and counteracted inflammation both in vitro and in vivo, thereby contributing to increased brain tolerance of ischemic injury with minimal side effects. This study provides a proof of concept for a novel class of neuroprotective nanoagents that might be beneficial for treatment of ischemic stroke and other RONS-related disorders.

show abstract

mentioning

confidence: 61%

Hollow Prussian Blue Nanozymes Drive Neuroprotection against Ischemic Stroke via Attenuating Oxidative Stress, Counteracting Inflammation, and Suppressing Cell Apoptosis

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cerebral ischemic stroke suppresses glucose metabolism in the brain, 12,42 and low glucose metabolism is closely related to mood disorders. 10,43,44 To examine whether MOOs influenced poststroke cerebral glucose metabolism, we performed 18 F-FDG PET-CT scan in PSD rats and quantified the standard uptake value (SUV) of 18 F-FDG.…”

Section: Moos Improve Glucose Metabolism and Restores Synapse Activmentioning

confidence: 99%

Morinda officinalis oligosaccharides ameliorate depressive‐like behaviors in poststroke rats through upregulating GLUT3 to improve synaptic activity

Zhu

Peng

et al. 2020

FASEB j.

View full text Add to dashboard Cite

Poststroke depression (PSD) is one of the most common psychiatric diseases afflicting stroke survivors, yet the underlying mechanism is poorly understood. The pathophysiology of PSD is presumably multifactorial, involving ischemia‐induced disturbance in the context of psychosocial distress. The homeostasis of glucose metabolism is crucial to neural activity. In this study, we showed that glucose consumption was decreased in the medial prefrontal cortex (mPFC) of PSD rats. The suppressed glucose metabolism was due to decreased glucose transporter‐3 (GLUT3) expression, the most abundant and specific glucose transporter of neurons. We also found Morinda officinalis oligosaccharides (MOOs), approved as an antidepressive Chinese medicine, through upregulating GLUT3 expression in the mPFC, improved glucose metabolism, and enhanced synaptic activity, which ultimately ameliorated depressive‐like behavior in PSD rats. We further confirmed the mechanism that MOOs induce GLUT3 expression via the PKA/pCREB pathway in PSD rats. Our work showed that MOOs treatment is capable of restoring GLUT3 level to improve depressive‐like behaviors in PSD rats. We also propose GLUT3 as a potential therapeutic target for PSD and emphasize the importance of metabolism disturbance in PSD pathology.

show abstract

“…Spinal cord injury patients were transplanted with SPIO-labeled autologous bone marrow CD34 + cells, and some of them showed a persistent hypointense signal around the lesion site on MRI ( Callera and de Melo, 2007 ). Zhang et al used spatiotemporal PET imaging to observe dynamic metabolic changes after iPSC transplantation in stroke patients and found that iPSCs may differentiate into a more specific cell type before improving recovery from cerebral injury ( Zhang et al, 2015a ). Moreover, cerebral blood flow can be monitored via simultaneous [ 15 O] H 2 O PET/MRI after stroke ( Werner et al, 2015 ).…”

Section: Transplantation Of 3d Brain Organoid Tissue For Poststroke Repairmentioning

confidence: 99%

The Application of Brain Organoid Technology in Stroke Research: Challenges and Prospects

Song

Zhao

Chen

et al. 2021

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Stroke is a neurological disease responsible for significant morbidity and disability worldwide. However, there remains a dearth of effective therapies. The failure of many therapies for stroke in clinical trials has promoted the development of human cell-based models, such as brain organoids. Brain organoids differ from pluripotent stem cells in that they recapitulate various key features of the human central nervous system (CNS) in three-dimensional (3D) space. Recent studies have demonstrated that brain organoids could serve as a new platform to study various neurological diseases. However, there are several limitations, such as the scarcity of glia and vasculature in organoids, which are important for studying stroke. Herein, we have summarized the application of brain organoid technology in stroke research, such as for modeling and transplantation purposes. We also discuss methods to overcome the limitations of brain organoid technology, as well as future prospects for its application in stroke research. Although there are many difficulties and challenges associated with brain organoid technology, it is clear that this approach will play a critical role in the future exploration of stroke treatment.

show abstract

Spatiotemporal PET Imaging of Dynamic Metabolic Changes After Therapeutic Approaches of Induced Pluripotent Stem Cells, Neuronal Stem Cells, and a Chinese Patent Medicine in Stroke

Cited by 21 publications

References 32 publications

Hollow Prussian Blue Nanozymes Drive Neuroprotection against Ischemic Stroke via Attenuating Oxidative Stress, Counteracting Inflammation, and Suppressing Cell Apoptosis

Hollow Prussian Blue Nanozymes Drive Neuroprotection against Ischemic Stroke via Attenuating Oxidative Stress, Counteracting Inflammation, and Suppressing Cell Apoptosis

Morinda officinalis oligosaccharides ameliorate depressive‐like behaviors in poststroke rats through upregulating GLUT3 to improve synaptic activity

The Application of Brain Organoid Technology in Stroke Research: Challenges and Prospects

Contact Info

Product

Resources

About